A practical reference on AOD-9604: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-02-19. Anything still debated is marked as such rather than presented as settled.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Fragment analog of human growth hormone |
| Sequence basis | hGH 176–191 region | Modified C-terminal fragment |
| Common synonyms | AOD-9604; AOD9604; hGH fragment | Research and trade names vary |
| Regulatory status | Not approved as a drug | Prohibited in competitive sport |
| Research code | AOD9604 | Used in scientific and patent literature |
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Large intakes of α-tocopherol result in increased urinary α-CEHC, so this appears to be a means of disposing of excess vitamin E. Alpha-tocopherol transfer protein is coded by the TTPA gene on chromosome 8. The binding site for RRR-α-tocopherol is a hydrophobic pocket with a lower affinity for beta-, gamma-, or delta-tocopherols, or for the stereoisomers with an S configuration at the chiral 2 site. Tocotrienols are also a poor fit because the double bonds in the phytic tail create a rigid configuration that is a mismatch with the α-TTP pocket. A rare genetic defect of the TTPA gene results in people exhibiting a progressive neurodegenerative disorder known as ataxia with vitamin E deficiency (AVED) despite consuming normal amounts of vitamin E. Large amounts of alpha-tocopherol as a dietary supplement are needed to compensate for the lack of α-TTP. The role of α-TTP is to move α-tocopherol to the plasma membrane of hepatocytes (liver cells), where it can be incorporated into newly created very low density lipoprotein (VLDL) molecules. These convey α-tocopherol to cells in the rest of the body. As an example of a result of the preferential treatment, the US diet delivers approximately 70 mg/d of γ-tocopherol, and plasma concentrations are on the order of 2–5 μmol/L; meanwhile, dietary α-tocopherol is about 7 mg/d, but plasma concentrations are in the range of 11–37 μmol/L. Affinity of α-TTP for vitamin E vitamers
== See also == Dimethylaminoethylindole Dimethyltryptamine/harmine Dimethyltryptamine/β-carbolines List of psychoactive plants List of substances used in rituals Psychedelic replication Substituted tryptamine
The Edman degradation is an alternative method for peptide sequencing that cleaves amino acid residues from the N-terminus of a peptide. In 1950 Edman designed a reaction with phenylthiocyanate (the idea for which was borrowed from a 1927 study by Bergmann, Kann and Miekeley ) to give phenylthiocarbamyl peptides followed by hydrolysis under relatively mild conditions to cleave N-terminal amino acid as phenylthiohydantoin. Phenylthiohydantoin is stable enough to undergo various sequencing procedures such as those which involve chromatography and mass spectrometry. This was an improvement on an earlier method proposed by Abderhalden and Brockmann in 1930 that demonstrated N-terminal amino acid conversion to a hydantoin under stronger hydrolytic conditions, where some cleavage of the residual peptide proved problematic. The primary advantage the Edman degradation has over the Bergmann degradation is the ease with which the residual peptide can re-enter the process due to retention of its structure throughout sequential cleaving. Repetition of the Bergmann degradation is presumably not as straightforward, as the remaining peptide is in amide form.
Sources: en.wikipedia.org
== Medical uses == Albiglutide was used for the treatment of type 2 diabetes in adults. It can be used alone (if metformin therapy is ineffective or not tolerated) or in combination with other antidiabetic drugs, including insulins. According to a 2015 analysis, albiglutide is less effective than other GLP-1 agonists for lowering glycated hemoglobin (HbA1c, an indicator for long-term blood glucose control) and weight loss. It also seems to have fewer side effects than most other drugs of this class, except for reactions at the injection site which are more common under albiglutide than, for example, under liraglutide.
Putin would have gone in anyway." According to Fried, it was probably the intervention of US president George W. Bush that forced Putin to halt hostilities in Georgia and the reset policy of Obama administration was a mistake.
The European Wound Management Association (EWMA) was founded in 1991. The association promotes the advancement of education and research into native epidemiology, pathology, diagnosis, prevention and management of wounds of all aetiologies. EWMA is an umbrella organisation linking wound management associations across Europe and a multidisciplinary group bringing together individuals and organisations interested in wound management. Currently, the association bridges 54 Cooperating Organisations (national wound care associations in Europe) and, in addition, partners with a considerable number of wound and wound related associations in and outside of Europe. Similar organizations include the European Tissue Repair Society, the Tissue Viability Society, the World Union of Wound Healing Societies, and the Wound Care Society. EWMA is an educational resource, organising conferences, contributing to international projects related to wound management, supporting the implementation of existing knowledge within wound management, and providing information on all aspects of wound management.
The United States and the Soviet Union engaged in competition vis-à-vis the arts. Cultural competition played out in Moscow, New York, London, and Paris. In 1946 America opened an exhibition called 'Advancing American Art' which gained popularity with the aims of expressing American art, in response the Soviets opened a respective exhibition showcasing Soviet Realism. The Soviets excelled at ballet and chess, the Americans at jazz and abstract expressionist paintings. The US funded its own ballet troupes, and both used ballet as political propaganda, using dance to reflect life style in the "battle for the hearts and minds of men." The defection of a premier dancer became a major coup. Chess was inexpensive enough—and the Russians always won until America unleashed Bobby Fischer. Vastly more expensive was the Space Race, as a proxy for scientific supremacy (with a technology with obvious military uses). As well when it came to sports the two countries both competed in the Olympics during the Cold War period which also created severe tension when the West boycotted the first Russian Olympics in 1980.
Sources: en.wikipedia.org
== Occurrence == Obsidian is found near volcanoes in locations which have undergone rhyolitic eruptions. It can be found in Argentina, Armenia, Azerbaijan, Australia, Canada, Chile, Georgia, Ecuador, El Salvador, Greece, Guatemala, Hungary, Iceland, Indonesia, Italy, Japan, Kenya, Mexico, New Zealand, Papua New Guinea, Peru, Russia, Scotland, the Canary Islands, Turkey and the United States. Obsidian flows which are so large that they can be hiked on are found within the calderas of Newberry Volcano (Big Obsidian Flow, 700 acres) and Medicine Lake Volcano in the Cascade Range of western North America, and at Inyo Craters east of the Sierra Nevada in California. Yellowstone National Park has a mountainside containing obsidian located between Mammoth Hot Springs and the Norris Geyser Basin, and deposits can be found in many other western U.S. states including Arizona, Colorado, New Mexico, Texas, Utah, and Washington, Oregon and Idaho.
=== Firestone recall and legal mandates === The Firestone recall in the late 1990s (which was linked to more than 100 deaths from rollovers following tire tread-separation), pushed the United States Congress to legislate the TREAD Act. The Act mandated the use of a suitable TPMS technology in all light motor vehicles (under 10,000 lb (4,500 kg)), to help alert drivers of under-inflation events. This act affects all U.S. light motor vehicles sold after September 1, 2007. Phase-in started in October 2005 at 20%, and reached 100% for models produced after September 2007. In the United States, as of 2008 and the European Union, as of November 1, 2012, all new passenger car models (M1) released must be equipped with a TPMS. From November 1, 2014, all new passenger cars sold in the European Union must be equipped with a TPMS. For N1 vehicles (trucks up to 3.5 tonnes), TPMS are not mandatory, but if a TPMS is fitted, it must comply with the regulation. On July 13, 2010, the South Korean Ministry of Land, Transport and Maritime Affairs announced a pending partial-revision to the Korea Motor Vehicle Safety Standards (KMVSS), specifying that "TPMS shall be installed to passenger vehicles and vehicles of GVW 3.5 tons or less, ... [effective] on January 1, 2013 for new models and on June 30, 2014 for existing models". Japan is expected to adopt European Union legislation approximately one year after European Union implementation. Further countries to make TPMS mandatory include Russia, Indonesia, the Philippines, Israel, Malaysia and Turkey.
A report by demographer William Frey suggests that as of 2019, 50.9% of Generation Z is white, 13.8% is black, 25.0% Hispanic, and 5.3% Asian. 29% of Generation Z are children of immigrants or immigrants themselves, compared to 23% of Millennials when they were at the same age. As of 2019, 13.7% of the U.S. population is foreign-born, compared to 9.7% in 1997, when the first members of Generation Z had their birth cries. Indeed, according to the Pew Research Center, in spite of the diminished flow of immigrants to the United States following the Great Recession, Generation Z is the most ethnically diverse yet seen. 52% of this generation is white. 25% is Hispanic. 14% is black, and 4% is Asian. Approximately 4% is multiracial, and this number has risen rapidly between 2000 and 2010. More specifically, the number of Americans who identify as mixed white and black has grown by 134% and those of both white and Asian extraction by 87%. For comparison, 44% of Millennials, 40% of Generation X, and 28% of the Baby Boomers identify as non-white. Research by the demographer Bill Frey suggests that at the national level, Hispanics and Asians are the fastest-growing racial minority groups in the United States while the number of Caucasians under the age of 18 has been declining since 2000. Overall, the number of births to Caucasian women in the United States dropped 7% between 2000 and 2018. Among foreign-born Caucasian women, however, the number of births increased by 1% in the same period.
== Professional organizations for clinical data management == International Network of Clinical Data Management Associations (INCDMA) aims at the promotion of collaboration among clinical data management groups around the world. It is an international forum for discussion of and feedback on current topics of relevance to the discipline of CDM. It is composed of members the boards of the SCDM, ACDM, DMB (France), PSDM (The Netherlands) who participate in the INCDMA proceedings and funding. It also regroups DM leaders and subject matter experts from Europe, North America, Israel, Japan, China and Australia. The Association for Clinical Data Management (ACDM) is a global organization founded in 1987 and is Empowering Excellence in Clinical Data Management. The ACDM represents a vibrant community of dedicated clinical research professionals who are passionate about enhancing the drug development process through fostering an environment that encourages continuous learning and the practical application of modern Clinical Data Management practices. With over 35 years of service to the data management community, the ACDM's unwavering commitment is to provide clear and effective platforms for its members to network, share experiences, and stay abreast of the latest regulations and standards in Clinical Data Management. Along with supporting members on their professional development journeys, offering opportunities to gain the skills and insights needed to excel in their careers and shape the future of data management.
The process of metalorganic vapour-phase epitaxy (MOCVD) entails pyrolysis of volatile organometallic compounds to give semiconductors, hard coatings, and other applicable materials. The reactions entail thermal degradation of precursors, with deposition of the inorganic component and release of the hydrocarbons as gaseous waste. Since it is an atom-by-atom deposition, these atoms organize themselves into crystals to form the bulk semiconductor. Raw polycrystalline silicon is produced by the chemical vapor deposition of silane gases:
Sources: en.wikipedia.org
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.
It was investigated in clinical trials for obesity, but it did not receive approval for that use in major markets. Results were generally modest or mixed, and it remains an experimental compound.
WADA lists it as a prohibited peptide hormone. Its use can be detected by laboratory methods, and athletes are subject to sanctions if it is found in samples.
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.